ARCHIVES

Two New Modalities Promising For Relapsed/Refractory NHL

This article is from The Cancer Letter archive.

Vol. 28 No. 1 | January 28, 2005

Download PDF Visit The Full Archive

Related Articles

Women’s Health Initiative Trial Produced $37.1 Billion in Returns

May 9, 2014

Loehrer To Direct IU Simon Cancer Center

March 5, 2010

Phase IIb Trial of Vintafolide-Docetaxel Combination Meets Primary Endpoint of Progression-Free Survival

March 28, 2014

Cancer Meetings For May, June, Future

April 27, 1990

Final Issue Of 1988

December 9, 1988

Health Canada Suspends Avastin Approval; CMS Has Taken No Action After FDA Decision

December 2, 2011